Margaret Rees’s research while affiliated with Oxford University Hospitals NHS Trust and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (225)


Chronic kidney disease and menopausal health: An EMAS clinical guide
  • Literature Review

November 2024

·

16 Reads

Maturitas

E. Cansu Cevik

·

C. Tamer Erel

·

·

[...]

·




Writing case reports: Sharing clinical experience to inform practice
  • Article
  • Full-text available

May 2024

·

18 Reads

·

1 Citation

Case Reports in Women s Health

Download





Vitamin D, Menopausal Health and COVID-19: Critical Appraisal of Current Data

January 2023

·

47 Reads

·

1 Citation

Inconsistency exists across studies conducted in postmenopausal women regarding the effect of vitamin D deficiency (VDD) and supplementation on several aspects of menopausal health, such as fractures, vasomotor symptomatology, cardiovascular disease (CVD), cancer and infections, including coronavirus disease 2019 (COVID-19). The aim of this review is to critically summarize the evidence provided by observational studies and randomized controlled trials (RCTs) of vitamin D supplementation in postmenopausal women with VDD. Observational studies have found that VDD is associated with an increased risk of falls and fractures after the menopause. VDD also has a negative effect on menopausal symptomatology. VDD, especially its severe form, is associated with an increased risk of CVD risk factors and CVD events. VDD is associated with increased risk and mortality from several cancer types and risk of infections. The evidence from RCTs regarding the effect of vitamin D supplementation on falls, fractures, menopausal symptoms, cardiovascular disease, cancer and infections is not robust. Thus, skeletal health may benefit only when vitamin D is co-administered with calcium, especially in those ≥70 years old and with severe VDD. There is no evidence of a favorable effect on menopausal symptoms or risk of CVD or cancer, except for a modest reduction in cancer-related mortality. Inconsistency still exists regarding its effect on infection risk, disease severity and mortality due to COVID-19.



Citations (70)


... Sexual problems are considered to be taboo subjects. Sexual health and wellbeing are extensively analyzed in the clinical guide entitled: "Sexual health and wellbeing and the menopause: an EMAS clinical guide" published in the current issue of Maturitas [1]. ...

Reference:

Menopause and sexual health: The elephant in the room
Sexual health and wellbeing and the menopause: An EMAS clinical guide
  • Citing Article
  • September 2024

Maturitas

... This case study complies with the CARE guidelines for Clinical Case Reporting (Gagnier et al., 2013;Riley et al., 2017), and incorporates a qualitative analysis. Case reports serve as concise communications that share clinical experiences, and the lessons learned from their management (Ngene & Rees, 2024). In this case study, we aim to highlight the needs of a family undergoing a developmental transition and the role of the CNF throughout this process. ...

Writing case reports: Sharing clinical experience to inform practice

Case Reports in Women s Health

... The main characteristics of GD include its higher prevalence in women [8] and the difficulty of distinguishing it from other diseases, even when symptoms are present [9]. For example, menopausal symptoms such as tachycardia and sweating are difficult to distinguish from GD [10]. Consequently, the delayed diagnosis of GD has become a significant health concern, leading to a decline in quality of life [11][12][13]. ...

EMAS position statement: Thyroid disease and menopause
  • Citing Article
  • April 2024

Maturitas

... Authors Kanakis et al. (2023) [14] updated the 2015 EMAS statement on TRT in older men with new research on late-onset hypogonadism and TRT through an expert consensus and literature review. Thus, TRT should only be offered to symptomatic older men with confirmed low testosterone concentrations after accounting for uncertainties regarding the long-term safety of this treatment. ...

EMAS position statement: Testosterone replacement therapy in older men
  • Citing Article
  • October 2023

Maturitas

... This is crucial as concerns may arise about unfeasibly long or short author lists [7]. In addition, there may be uncertainty about whether the authors and their institutions had the expertise to provide the reported clinical care [8]. Author order in the contributor statement has to be the same as that of the submission title page. ...

Editors, publication ethics and maintaining the integrity of the scientific record
  • Citing Article
  • August 2023

Maturitas

... Vitamin D levels, as well as VDR expression, decrease with age, which is of particular importance for postmenopausal women, who, due to the cessation of estrogen synthesis and the consequent lack of its protective effect, are at greater risk of reduced bone mass, cardiovascular disease, metabolic disorders, unfavorable lipid profiles, diabetes, and atherosclerosis with all of its long-term consequences [22][23][24]. In addition, serum antioxidant activity decreases during the aging process, thus increasing the risk of oxidative stress, which, in turn, is involved in the initiation of the inflammatory process [25,26]. ...

Vitamin D, Menopausal Health and COVID-19: Critical Appraisal of Current Data

... La deficiencia de vitamina D se ha asociado con una baja masa ósea, un aumento del riesgo de fracturas, enfermedades cardiovasculares, cáncer y ciertos trastornos infecciosos, como las infecciones respiratorias agudas y el COVID-19. Aunque la suplementación puede mejorar algunos aspectos de la salud, como el perfil lipídico y la glucosa en sangre, esta no tiene un impacto significativo en la incidencia de eventos cardiovasculares o cáncer y su efecto en los síntomas menopáusicos es limitado (33). Volumen embargo, presentan desventajas como la falta de especificidad de los anticuerpos utilizados y la interferencia significativa, lo que limita su capacidad para cuantificar formas individuales de vitamina D. La reactividad cruzada entre metabolitos similares puede introducir errores y disminuir la especificidad del método, y la calidad del anticuerpo utilizado es crucial para la calidad del ensayo. ...

EMAS position statement: Vitamin D and menopausal health
  • Citing Article
  • December 2022

Maturitas

... A quarter of menopausal women are so severely affected by their symptoms that they consider resigning from work, and according to the Women and Equalities Committee (Women and Equalities Committee, 2022) in just one year (2019), a million workdays were lost due to menopausal symptoms. Importantly, well-being and health during and after menopause are moderated by several psychosocial factors, including socioeconomic status, prior life experience (particularly early life adversity), ethnicity and culture, employment factors, and premenopausal health (Riach and Rees, 2022;Shanmugan et al., 2017). This points to the importance of considering diversity in menopausal experiences and the need to examine the effects of menopause in specific groups of individuals for whom menopause may unveil particularly difficult symptoms. ...

Diversity of menopause experience in the workplace: Understanding confounding factors
  • Citing Article
  • August 2022

Current Opinion in Endocrine and Metabolic Research

... During the last two decades, after a reappraisal of the evidence emerging from the Women's Health Initiative (WHI) trial and by pooling data from other well-designed studies and meta-analyses, menopausal hormone therapy (MHT) has regained its position in the therapeutic armamentarium [1,2]. All scientific societies converge on the notion that MHT is the most effective treatment for the relief of bothersome vasomotor symptomatology (VMS) in postmenopausal women [1][2][3][4]. It may also reduce the risk of cardiovascular disease (CVD), if initiated promptly [i.e. in women <60 years of age or within 10 years since their final menstrual period (FMP)], providing a 'window of opportunity' [1][2][3][4]. ...

Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society
  • Citing Article
  • September 2022

Maturitas

... During this period, women may encounter irregular menstrual cycles, hot flashes, mood changes, sleep disturbances, or metabolic imbalances. [2] Menopause itself marks the conclusion of the reproductive phase in a woman's life, signified by the permanent cessation of menstruation due to the loss of ovarian follicular function. This physiological event is diagnosed retrospectively after a continuous absence of menstruation for 12 consecutive months, with the average age of occurrence being 51 years. ...

The essential menopause curriculum for healthcare professionals: A European Menopause and Andropause Society (EMAS) position statement
  • Citing Article
  • April 2022

Maturitas